Samsara Biocapital, LLC 13F holdings
Samsara Biocapital, LLC reported 24 positions with a total reported value of $1.2B as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: SRRK SCHOLAR ROCK HLDG CORP (31.2%), ALMS ALUMIS INC (14.7%), MLYS MINERALYS THERAPEUTICS INC (13.0%), SEPN SEPTERNA INC (8.7%), ALMR ALAMAR BIOSCIENCES INC (5.5%). Against 2026-03-31 it opened 4 new positions and exited 2. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Samsara Biocapital, LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
24 largest of 24 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| SRRK SCHOLAR ROCK HLDG CORP | 6,897,652 | $379.4M | 31.2% |
| ALMS ALUMIS INC | 6,345,219 | $178.6M | 14.7% |
| MLYS MINERALYS THERAPEUTICS INC | 5,871,018 | $158.4M | 13.0% |
| SEPN SEPTERNA INC | 3,149,128 | $105.5M | 8.7% |
| ALMR ALAMAR BIOSCIENCES INC | 2,480,310 | $67.2M | 5.5% |
| NGNE NEUROGENE INC | 1,717,127 | $54.0M | 4.4% |
| KLRS KALARIS THERAPEUTICS INC | 12,881,175 | $52.4M | 4.3% |
| SGP SPYGLASS PHARMA INC | 2,109,953 | $47.0M | 3.9% |
| STRO SUTRO BIOPHARMA INC | 1,062,872 | $35.3M | 2.9% |
| IVA INVENTIVA SA | 6,314,805 | $23.9M | 2.0% |
| JBIO JADE BIOSCIENCES INC | 736,237 | $16.4M | 1.3% |
| PBLS PARABILIS MEDICINES INC | 556,044 | $15.2M | 1.3% |
| VTVT VTV THERAPEUTICS INC | 298,496 | $11.2M | 0.9% |
| AQST AQUESTIVE THERAPEUTICS INC | 2,500,000 | $10.4M | 0.9% |
| NKTX NKARTA INC | 3,507,666 | $9.9M | 0.8% |
| ARTV ARTIVA BIOTHERAPEUTICS INC | 954,861 | $9.3M | 0.8% |
| RANI RANI THERAPEUTICS HLDGS INC | 10,369,159 | $7.9M | 0.6% |
| AGMB AGOMAB THERAPEUTICS NV | 600,000 | $7.8M | 0.6% |
| ABVX ABIVAX SA | 55,095 | $7.3M | 0.6% |
| XFOR X4 PHARMACEUTICALS INC | 1,395,587 | $6.5M | 0.5% |
| ELOX ELOXX PHARMACEUTICALS INC | 400,000 | $5.6M | 0.5% |
| CHRS COHERUS ONCOLOGY INC | 3,428,571 | $4.8M | 0.4% |
| UPB UPSTREAM BIO INC | 353,717 | $2.4M | 0.2% |
| GOSS GOSSAMER BIO INC | 7,222,559 | $1.2M | <0.1% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 4 in all · reported value as of 2026-06-30
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 2 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| ARCELLX INC | 60,873 | $7.0M | 0.7% |
| PVLA PALVELLA THERAPEUTICS INC NE | 38,432 | $4.8M | 0.5% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| IVA INVENTIVA SA | 5,194,805 | 6,314,805 | +21.6% | $23.9M |
| RANI RANI THERAPEUTICS HLDGS INC | 8,500,000 | 10,369,159 | +22.0% | $7.9M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| JBIO JADE BIOSCIENCES INC | 968,798 | 736,237 | -24.0% | $16.4M |
| UPB UPSTREAM BIO INC | 736,047 | 353,717 | -51.9% | $2.4M |
| XFOR X4 PHARMACEUTICALS INC | 1,832,566 | 1,395,587 | -23.8% | $6.5M |
| KLRS KALARIS THERAPEUTICS INC | 12,948,081 | 12,881,175 | -0.5% | $52.4M |
| ABVX ABIVAX SA | 56,581 | 55,095 | -2.6% | $7.3M |
CIK 1744967 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
